Recon: Drugmakers ignore Trump on promised price cuts

• Drugmakers ignore Trump on promised price cuts (Politico)
• More than $100 Billion Spent on M&A in the First 6 Months of 2018 (BioSpace)
• GSK director sued over US opioid epidemic (Financial Times)
• Drugmakers try evasion, tougher negotiations to fight new U.S. insurer tactic (Reuters)
• Mercy partners with Johnson & Johnson to evaluate medical device safety (St. Louis Business Journal-$) (Fierce)

• Takeda to sell Osaka headquarters ahead of Shire purchase (Nikkei Asian Review) (Endpoints)
• Sinclair Pharma Confirms Approach From China Grand Enterprises (Bloomberg) (Reuters)
• US FDA clears troubled API plants following two Form 483s, says Dr. Reddy’s (in_PharmaTechnologist)
• Vertex calls NHS England ‘outrageous’ as Orkambi talks stall again (PMLiVE) (pharmaphorum)
• NICE turns down BMS' blockbuster Opdivo for urothelial carcinoma (Pharmafile) (PharmaTimes)
• Abivax up on mixed HIV data (BioPharma Dive) (PMLiVE) (pharmaphorum)
• Combining drugs could help tackle superbugs (The Telegraph) (STAT)
• Timeline: Britain's National Health Service turns 70 (Reuters)
• NHS70: How Has Technology Changed Our Healthcare? (Forbes)
• International UDI effort for implants gets real-world test (Health Data Management)

• Zynerba Scraps Development of THC Prodrug ZYN001 after Failed Trial (GEN) (Endpoints)
• Regeneron's CEO has been outspoken about drug price hikes, but one of his company’s drugs just got more expensive (Business Insider)
• After a decade working for pharma, AHIP CEO Matt Eyles pegs drug pricing as his top priority (Fierce)
• Jefferies says Gilead is poised for turnaround—and JAK inhibitor could be key (Fierce)
• Non-opioid painkillers: agony column (Financial Times)
• Review article: Chimeric Antigen Receptor Therapy (NEJM)
• Biopharma has a new big idea for making cancer immunotherapy work better (STAT-$)
• The biotech scorecard for the third quarter: 12 make-or-break industry events to watch (STAT-$)
• Pharma is Exploring How to Maximize ICH Q12 Value in Practice; Q12 EWG Encourages Feedback (IPQ)
• Augmented Engagement: The Future of Pharma And Health Care Marketing (Forbes)
• Allergan Beats Challenge Over Company Stock in 401(k) Plan (Bloomberg)
• an new data aggregators shift the balance of power away from pharma? (PMLiVE)
• Fagron Sterile Services Issues Voluntary Nationwide Recall of Neostigmine Methylsulfate 1mg/mL, 5mg per 5mL and Neostigmine Methylsulfate 1mg/mL, 3mg per 3mL, in a 5mL syringe Due to Mislabeling (FDA)

• Data show Imnovid-based triple therapy PFS benefit in blood cancer (PharmaTimes)
• FDA-Mandated Trials: No Excess Risk With LABA Combo in Asthma (Medscape)
• Nobel prize winning technology reveals common herpes virus structure (MRC)
• New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI (inotersen) for the Treatment of Hereditary ATTR Amyloidosis (Press)
• Kalytera Announces Pre-IND Meeting Date with FDA (Press)

• AHA, other groups call for medical device security government guidance, financial support (Healthcare IT News)
• Natera Opens New Front in Prenatal Test Battle With Illumina (Bloomberg)
• FDA pledges 'efficient regulation' of mobile health apps (Healthcare Dive)
• Boston Scientific Can't Toss 800 Pelvic Mesh Suits (Law360-$)

• Roe v. Wade vs. Stem Cell Study? (Bloomberg)
• IPO Releases List of Top 300 Patent Holders for 2017 (Patent Law Weblog)
• Americans broadly favor government funding for medical and science research (Pew Research)
• CVS Health CEO 'surprised' by Azar's comments on drug prices (The Hill)
• It’s time for methadone to be prescribed as part of primary care (STAT)
• Amazon's PillPack Deal Adds Drama To Rite Aid-Albertsons Vote (Forbes)
• The Trump administration could make fee-based doctors more affordable for seniors  (CNBC)
• How FDA’s recall system fails consumers (Politico)
• FDA Renews Cautions Against Consumption of Kratom Following Conclusion of Salmonella Investigation (The National Law Review)

• FDA Advisory Committee Calendar

• Food Additives and Drugs Change Antibiotic Effectiveness (GEN)
• Recall – SAM XT Extremity Tourniquet (MHRA)
• Microbiome startup Nextbiotix raises €7M to tackle inflammatory bowel diseases (Fierce)
• UK’s genome sequencing project will hit 100,000 by year-end (PharmaTimes)
• MSD’s antiviral Prevymis fails to win NICE backing (PharmaTimes)
• Forendo joins race to develop endometriosis drugs (pharmaphorum)
• Review finds medical benefits of cannabis-based drugs (pharmaphorum)
• Clovis Oncology Receives EMA Validation for its Application for a New Indication for Rubraca (rucaparib) as Maintenance Treatment for Women with Recurrent Ovarian Cancer (Press)

• Another IPO frenzy? Two US biotechs head to Hong Kong for a public market debut (Endpoints)
• CRISPR-Induced Mutations Give Wing to a Butterfly Effect (GEN)
• Cellect, denovoMATRIX start stem cell research project (Fierce)
• China's Sinovac raises $87 million and aborts plan to go private (The Pharma Letter)
• Boehringer steps up contract manufacturing at China facility (The Pharma Letter)
• SNUBH, Sanofi inks deal to cooperate on clinical development (Korea Biomedical Review)
• SMC, Intel to create AI-based medical research infrastructure (Korea Biomedical Review)
• New South Korean Guidelines for Medical Device Cybersecurity Management (Emergo Group)
• Philips powers first tele-intensive care eICU program in Japan (Press)
• Outcome documents of the Science Board (PMDA)
• ICH Assembly in Kobe, Japan, 2 to 7 June 2018 (Swissmedic)
• Xu Jinghe,Deputy Commissioner of CNDA,attends the China US Conference on the Development and Evaluation of Oncology Drugs (CFDA)

• Pharma companies throng Gujarat to set up new units (Times of India)
• Central aid package to help medical device parks set up common facilities; Rs.100 crore budgeted for 2018-20 (Pharmabiz)
• CDSCO sets up panel to weigh ‘trace and track’ mechanism for top 300 drug brands, report expected in 4 months (Pharmabiz)
• Modi Rushes to Insure Half a Billion Indians Before Election (Bloomberg)

• Anavex sets up trial of ‘triple-action’ Alzheimer’s drug (PMLiVE)

• What Big Pharma pays your doctor (The Conversation)
• Purdue Pharma halts marketing of opioids in Canada (The Globe and Mail)

• Maintaining healthy vision may help keep brain in shape, too (Reuters)
• Carrot, a Silicon Valley startup, takes a novel approach to funding IVF (The Economist)
• What Happens When You See The Same Doctor? Link With Lower Death Rates (Forbes)
• Alfred Alberts, Unsung Father of a Cholesterol Drug, Dies at 87 (NYT)